We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Corvus Pharmaceuticals Inc | NASDAQ:CRVS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.32 | 18.50% | 2.05 | 1.07 | 2.20 | 2.08 | 1.73 | 1.81 | 381,059 | 05:00:04 |
Corvus will present data on CPI-818 in two poster sessions:
Poster Presentations:
Poster 1571: | Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor that Preferentially Blocks the Growth of T Lymphoma Cells. |
Presenter: | Patrick Ng, PhD, Corvus Senior Scientist |
Poster Session: | 625: Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster I |
Date and Time: | Saturday, December 7 from 5:30 pm – 7:30 pm ET |
Location: | Poster Hall / Hall B, Level 2 / Orange County Convention Center |
Poster 4030: | A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2 Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma. |
Presenter: | Mehrdad Mobasher, M.D., Corvus Vice President and Chief Medical Officer |
Poster Session: | 624: Hodgkin Lymphoma and T/NK Cell Lymphoma – Clinical Studies: Poster III |
Date and Time: | Monday, December 9, 2019 from 6:00 pm – 8:00 pm ET |
Location: | Poster Hall / Hall B, Level 2 / Orange County Convention Center |
About Corvus Pharmaceuticals Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus’ lead product candidates are ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, and CPI-006, a humanized monoclonal antibody directed against CD73 that exhibits immunomodulatory activity and blockade of adenosine production. These candidates are being studied in ongoing Phase 1 and 2 clinical trials in patients with a wide range of advanced solid tumors. Ciforadenant is being evaluated in a successive expansion cohort trial examining its activity both as a single agent and in combination with an anti-PD-L1 antibody. CPI-006 is being evaluated in a multicenter Phase 1/1b clinical trial as a single agent, in combination with ciforadenant, and with pembrolizumab. The Company’s third clinical program, CPI-818, an oral, small molecule drug that has been shown to selectively inhibit ITK, is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT: Leiv Lea Chief Financial Officer Corvus Pharmaceuticals, Inc. 650-900-4522 LLea@corvuspharma.com
MEDIA CONTACT: Sheryl Seapy W2O pure +1 213-262-9390 sseapy@purecommunications.com
1 Year Corvus Pharmaceuticals Chart |
1 Month Corvus Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions